Inovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer Conference
November 10, 2017 10:27 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that two of its cancer immunotherapies demonstrated antigen-specific T-cell...
Inovio Pharmaceuticals to Participate In Upcoming Investment Conferences
November 09, 2017 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences:...
Inovio Pharmaceuticals Reports 2017 Third Quarter Financial Results
November 08, 2017 16:05 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended September 30, 2017. Total revenue was...
Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhibitor
November 01, 2017 09:18 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today initiated a phase 1b/2a immuno-oncology trial in patients with newly diagnosed glioblastoma...
Inovio Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 8, 2017
October 26, 2017 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 third...
Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study
October 24, 2017 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced results of a study in which a DNA vaccine provided 100% protection for non-human...
Inovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 Checkpoint Inhibitor in Advanced Bladder Cancer
October 16, 2017 07:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced initiation of a phase 1b/2 immuno-oncology trial to evaluate Genentech/Roche’s...
Inovio’s Positive Zika Vaccine Clinical Study Data Published in New England Journal of Medicine
October 05, 2017 07:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) reported today on positive safety and immune response results from a first-in-man, multi-center...
Inovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Preclinical Studies
September 21, 2017 08:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the development of its DNA-based monoclonal antibody program received a boost...
Inovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection
September 18, 2017 08:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Korean Ministry of Food and Drug Safety approved the initiation of a...